After decades of Alzheimer’s research that led to dead ends, including 123 drugs that failed, top researchers in the field say they are far more confident now of producing an effective treatment. Their optimism has been building ahead of the Alzheimer’s Association International Conference (AAIC), which starts on Saturday in Washington, DC. New experimental drugs […]
Featured Posts
R&D/Pipelines Report 2022: Innovating to turn the tide - The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.A vast majority of Americans say the Medicare health program for the elderly should be able to negotiate with drug companies to set lower medication prices, a practice currently prohibited by law, according to a survey released on Friday. The poll conducted by the Kaiser Family Foundation found that 87 percent of people surveyed want […]
VANCOUVER, July 17, 2015 /PRNewswire-USNewswire/ — The last decade has seen investment in HIV prevention R&D move beyond bench science and clinical trials to include significant funding for implementation research for proven prevention options, such as pre-exposure prophylaxis (PrEP) and voluntary medical male circumcision (VMMC), according to a new report from the HIV Vaccines and […]
The European Commission approval is based upon Phase III clinical trial – Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as low as 6% at 48 weeks and 8% at 144 weeks [HIV-1 RNA ≥50 copies/mL: 6% Reyataz/cobicistat arm and 4% Reyataz/ritonavir arm at 48 weeks; 8% Reyataz/cobicistat arm and 5% Reyataz/ritonavir arm at 144 […]
NORTH CHICAGO, Ill., July 17, 2015 /PRNewswire/ — C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study […]
Amgen Inc on Thursday said some patients with a deadly form of leukemia experienced complete remission after being treated with its Blincyto drug in a midstage clinical trial, results that could eventually lead to an expanded approval of the pricy cancer medicine. While providing few details, the world’s largest biotechnology company said the drug, which […]
THOUSAND OAKS, Calif., July 16, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL). The investigational study showed blinatumomab monotherapy induced a complete remission […]
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and […]
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe, North Africa, Russia and certain Middle Eastern markets. Alprolix is a recombinant factor IX Fc fusion protein product candidate […]
Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies Inhibrx’s technology may offer best-in-class approach for agonist antibodies New program further expands Five Prime’s immuno-oncology pipeline and potential for combination therapies SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., July 15, 2015 (GLOBE NEWSWIRE) — Five Prime Therapeutics, […]